The Company was specifically named Antisense Therapeutics to connote its technology, “antisense oligonucleotide product development”. It has spent more than 2 decades developing an awareness and appreciation of this by pharma, biotechs, instos, retail shareholders, regulatory authorities; and importantly DMD advocacy. All of these groups are anticipating the potentially game-changing DMD Phase IIb CT results in 2024. The proposed name change to Percheron will serve no commercial purpose whatsoever, but it will elicit market confusion and Antisense Therapeutics will no doubt drop off the radar of many of these groups. A name change to Percheron is lunacy. The Company is not raising horses. All thinking shareholders should vote “NO” to the name change resolution as I certainly will.
